Clinical trials: Pancreatic Metastasis
Pancreatic Cancer
Radiation Therapy and Docetaxel With Either Fluorouracil or Cisplatin as First-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as docetaxel, fluorouracil, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the…
- Trial name
- NCT00112697
- Testing
- cisplatin, docetaxel, fluorouracil
- Where
- 10 sites in France
- Volunteers
- 71 people
- Sponsor
- UNICANCER
Advanced Solid Tumor, Metastatic Solid Tumor
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-313…
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Prostate Cancer, Pancreas Cancer
- Trial name
- NCT06545942
- Testing
- MOMA-313, Olaparib
- Where
- 18 sites in United States, Spain and 1 more
- Volunteers
- 220 people
- Sponsor
- MOMA Therapeutics
Solid Tumor
A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors
Genes contain genetic code which tell the body which proteins to make. Some types of cancer are caused by changes, or mutations, in a gene called KRAS.
- Trial name
- NCT06364696
- Testing
- ASP4396
- Where
- 7 sites in United States
- Volunteers
- 60 people
- Sponsor
- Astellas Pharma Inc
Pancreatic Cancer
Hydroxychloroquine and Chlorphenesin Carbamate in Combination With mFOLFIRINOX in Pancreatic Cancer
Pancreatic cancer is the 8th most prevalent cancer in Korea, and its 5-year overall survival rate has shown less than 10% due to its dismal prognosis.
- Trial name
- NCT05083780
- Testing
- Chlorphenesin Carbamate, Hydroxychloroquine
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- Changhoon Yoo
Venous Thromboembolism, Metastatic Pancreatic Cancer
The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer
The aim of this Phase 3 study is to evaluate the efficacy of Kinisoquin™ as compared to the placebo in prevention of thromboembolic events in patients with metastatic or locally advanced pancreatic cancer.
- Conditions
- Venous Thromboembolism, Metastatic Pancreatic Cancer, Locally Advanced Pancreatic Adenocarcinoma
- Trial name
- CATIQ P3 (NCT06861088)
- Testing
- Kinisoquin™
- Where
- 3 sites in United States
- Volunteers
- 480 people
- Sponsor
- Quercis Pharma AG
Pancreas Cancer
Vactosertib With Nal-IRI/FL in Metastatic Pancreatic Ductal Adenocarcinoma.
To determine recommended phase 2 dose and to evaluate the safety of vactosertib in combination with nal-IRI/FL in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) who have failed first-line gemcitabine and…
- Trial name
- NCT04258072
- Testing
- Vactosertib
- Where
- South Korea
- Volunteers
- 24 people
- Sponsor
- Samsung Medical Center
Pancreatic Ductal Adenocarcinoma (PDAC)
Intraperitoneal Paclitaxel With NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal Carcinomatosis
This goal of this clinical trial is to learn whether the drug combination of intraperitoneal paclitaxel (chemotherapy given directly into the abdominal cavity) and intravenous NALIRIFOX (chemotherapy given into a vein, including…
- Trial name
- NCT07030283
- Testing
- Paclitaxel, NALIRIFOX
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Colorado, Denver
Metastatic Colorectal Cancer (CRC), Locally Advanced Colorectal Cancer
Study Evaluating the Safety Feasibility and Efficacy of ODI-2001 Vaccine, a Personnalized Immunotherapy in Patients With Metastatic or Locally Advanced Colon Cancer or Pancreatic Cancer
This is a phase 1, open-label, multicentric study evaluating the safety, feasibility and efficacy of ODI-2001, a personnalized therapeutic cancer vaccine composed of DNA neoantigen vaccine, Modified Vaccinia virus Ankara (MVA)…
- Conditions
- Metastatic Colorectal Cancer (CRC), Locally Advanced Colorectal Cancer, Metastatic Pancreatic Cancer, Locally Advanced Pancreatic Cancer
- Trial name
- ODI-2001-01 (NCT07587827)
- Testing
- Personalized cancer vaccine including : DNA neoantigen vaccine, MVA viral vector and Ipilimumab (anti-CTLA4)
- Where
- 2 sites in France
- Volunteers
- 77 people
- Sponsor
- Centre Georges Francois Leclerc
Pancreatic Cancer
Phase I/II Study of Oral S-1 Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
To assess the usefulness of Gemcitabine plus S-1 therapy based on the antitumor effect and survival period. By performing a phase I/II study of this combination in patients with inoperable or with postoperative pancreatic cancer.
- Trial name
- NCT00209677
- Testing
- Gemcitabine, S-1
- Where
- Japan
- Volunteers
- 40 people
- Sponsor
- Hokkaido Gastrointestinal Cancer Study Group
Quality of Life, Locally Advanced Pancreatic Carcinoma
Quality of Life With Nutritional Supplementation in Patients With Locally Advanced/Metastatic Pancreatic Cancer.
Metastatic pancreatic cancer has a poor prognosis, with approximately one-third of patients experiencing poor quality of life at six months.
- Conditions
- Quality of Life, Locally Advanced Pancreatic Carcinoma, Metastatic Pancreatic Cancer
- Trial name
- FOODPANC (NCT05360745)
- Testing
- ARACOMPLEX®
- Sponsor
- Fundacion para la Excelencia y la Calidad de la Oncologia
Colon Cancer, Rectum Cancer
Phase I of SGM-101 in Patients With Cancer of the Colon, Rectum or Pancreas
This study evaluates the safety and performance of SGM-101, a Carcinoembryonic Antigen (CEA)-specific chimeric antibody conjugated with a NIR emitting fluorochrome, for the visualization of CEA-expressing cancers during surgery.
- Conditions
- Colon Cancer, Rectum Cancer, Pancreas Cancer, Metastatic Colorectal Cancer
- Trial name
- NCT02973672
- Testing
- SGM-101
- Where
- 3 sites in Netherlands
- Volunteers
- 75 people
- Sponsor
- Surgimab
Pancreatic Cancer
3-AP and Gemcitabine in Treating Patients With Recurrent, Unresectable, or Metastatic Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy, such as 3-AP and gemcitabine, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00078975
- Testing
- gemcitabine hydrochloride, triapine
- Where
- 4 sites in Canada
- Volunteers
- 26 people
- Sponsor
- University Health Network, Toronto
Colorectal Cancer, Pancreatic Ductal Cancer
A Study to Investigate BGB-3245 (Brimarafenib) With Panitumumab in Participants With Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers
The primary objectives of Part 1 of this study are to: Assess the safety and tolerability of the combination of BGB-3245 and panitumumab in participants with advanced or metastatic colorectal cancer (CRC) with a known mutation…
- Conditions
- Colorectal Cancer, Pancreatic Ductal Cancer, Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers
- Trial name
- NCT06194877
- Testing
- BGB-3245, Panitumumab
- Where
- 5 sites in United States, Australia
- Volunteers
- 13 people
- Sponsor
- MapKure, LLC
Foregut Adenocarcinoma, Esophageal Adenocarcinoma
Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels
This is a randomized, open label, single-center, phase 2, randomized controlled trial of sequential cytoreductive intervention versus standard of care therapy for patients with intervenable oligometastatic (stage IV) cancer of…
- Conditions
- Foregut Adenocarcinoma, Esophageal Adenocarcinoma, Gastroesophageal Adenocarcinoma, Gastric Adenocarcinoma
- Trial name
- OLIGOMETS (NCT07282912)
- Testing
- Sequential cytoreductive intervention, Signatera Genome ultra-sensitive ctDNA blood test
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Yale University
Pancreatic Cancer
Gemcitabine, 5-Fluorouracil, and Radiation Therapy in the Treatment of Non-Metastatic Pancreatic Cancer
The purpose of this study is to test a new treatment of pancreatic cancer that cannot be removed by surgery. This treatment is a Phase I dose escalation research study which will combine one drug at increasing doses with a fixed…
- Trial name
- NCT00251355
- Testing
- Gemcitabine, 5-Fluorouracil, Radiation Therapy
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Dana-Farber Cancer Institute
Metastatic Pancreatic Cancer
Disulfiram-Copper Gluconate in Met Pancreas Cancer w Rising CA19-9 on Abraxane-Gemzar, FOLFIRINOX or Gemcitabine
This is an open-label Phase 2 Pilot study to evaluate Disulfiram + Copper Gluconate in patients metastatic pancreatic cancer whose CA-19-9 levels rise while receiving nab-paclitaxel (Abraxane) plus gemcitabine (Gemzar) or…
- Trial name
- NCT03714555
- Testing
- Safety Laboratories, AE Assessment, Physical Exam
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- HonorHealth Research Institute
Gastrointestinal Neoplasms
A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)
This study will check how well a new medicine, Risvutatug rezetecan, (Ris-Rez, also known as GSK5764227) works, how safe it is and how the body handles it in participants all around the world with advanced inoperable or…
- Trial name
- NCT06885034
- Testing
- Risvutatug Rezetecan
- Where
- 85 sites in United States, Australia and 17 more
- Volunteers
- 346 people
- Sponsor
- GlaxoSmithKline
Pancreatic Cancer, Liver Metastases
The Significance and Indications of Surgery for Synchronous Liver Metastatic Pancreatic Cancer
To explore the clinical characteristics of pancreatic cancer patients with liver metastases who can benefit from surgery, and to develop evaluation criteria for surgical indications, so as to provide basis for comprehensive…
- Conditions
- Pancreatic Cancer, Liver Metastases, Surgery, Adjuvant Therapy
- Trial name
- PCLM:CSSG (NCT06873178)
- Where
- China
- Volunteers
- 50 people
- Sponsor
- China-Japan Friendship Hospital
Pancreas Cancer
Perfusion Assessment With Contrast-Enhanced EUS in Locally Advanced and Metastatic Pancreatic Cancer
Patients with non-resectable pancreatic cancer have a poor prognosis.The analysis of prognostic factors before treatment may be helpful in selecting appropriate candidates for chemotherapy and determining treatment strategies.
- Trial name
- PEACE (NCT03513198)
- Testing
- Endoscopic ultrasound (including fine needle aspiration), Contrast-enhanced endoscopic ultrasound (CE-EUS), Endoscopic ultrasound elastography (EG-EUS)
- Volunteers
- 200 people
- Sponsor
- University of Medicine and Pharmacy Craiova
Solid Tumors, Neoplasms (Cancer / Tumors)
Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid Tumor
The goal of this clinical trial is to learn if Trastuzumab Rezetecan can treat advanced solid tumors with HER-2 expression in adult participants.
- Conditions
- Solid Tumors, Neoplasms (Cancer / Tumors), Advanced Malignant Solid Neoplasm, Locally Advanced Malignant Solid Neoplasm
- Trial name
- NCT07631884
- Testing
- Trastuzumab Rezetecan
- Volunteers
- 15 people
- Sponsor
- Haihua Yuan
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.